Bio-TechneMEX:TECH 83 ROA % is 8.06% as of Mar. 2026, which is 11% above its 10-year median of 7.28. GuruFocus rates MEX:TECH with a GF Score™ of 83/100 and a GF Value™ of MXN1,117.60. The stock has 8 warning signs investors should review. Among 1,422 Biotechnology companies, Bio-Techne ranks better than 87.06% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Bio-Techne's annualizedNet Income for the quarter that ended in Mar. 2026 was MXN3,682 Mil.
Bio-Techne's average Total Assets over the quarter that ended in Mar. 2026 was MXN45,709 Mil. Therefore, Bio-Techne's annualized ROA % for the quarter that ended in Mar. 2026 was 8.06%.
The historical rank and industry rank for Bio-Techne's ROA % or its related term are showing as below:
MEX:TECH'
s ROA % Range Over the Past 10 Years
Min: 2.79 Med: 7.28 Max: 11.94
Current: 4.28
During the past 13 years, Bio-Techne's highest ROA % was 11.94%. The lowest was 2.79%. And the median was 7.28%.
MEX:TECH's ROA % is ranked better than 87.06% of 1422
companies
in the Biotechnology industry
Industry Median: -32.87
vs MEX:TECH: 4.28
Bio-Techne (MEX:TECH) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Bio-Techne ROA % Related Terms
Bio-Techne ROA % Historical Data
* Premium members only.
The historical data trend for Bio-Techne's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Bio-Techne's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Techne ROA % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Techne's ROA % distribution charts can be found below:
* The bar in red indicates where Bio-Techne's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Bio-Techne (MEX:TECH) has a ROA % of 8.06% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Bio-Techne and its competitors. This is 11% above median its historical median of 7.28. Over the past decade, Bio-Techne's ROA % has ranged from 2.79 to 11.94. According to the industry distribution chart, Bio-Techne ranks #184 out of 1422 companies in the Biotechnology industry, placing it in the top 12.9%.
Is Bio-Techne's ROA % too high?
Bio-Techne's current ROA % of 8.06% is 11% above median its 10-year median of 7.28. Over the past 10 years, this metric has ranged from a low of 2.79 to a high of 11.94. Based on the distribution chart, Bio-Techne ranks #184 out of 1422 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bio-Techne has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does Bio-Techne's ROA % compare to HALO and IBRX?
According to the Biotechnology industry distribution chart, Bio-Techne ranks #184 out of 1422 companies for ROA %. This places Bio-Techne in the top 13% of its industry — outperforming the majority of peers. Historically, Bio-Techne's own ROA % has ranged from 2.79 to 11.94 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Bio-Techne and its competitors. Bio-Techne's current ROA % is 8.06%, which is 11% above median its own 10-year median of 7.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Techne stock overvalued right now?
Bio-Techne (MEX:TECH) has a current ROA % of 8.06%. The stock's GF Value™ is MXN1,117.60, compared to a current price of MXN1,090.00 — trading 2.5% below its estimated fair value. The current ROA % is 8.06%, which is 11% above median its 10-year median of 7.28. Bio-Techne's overall GF Score™ is 83/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Bio-Techne (MEX:TECH), the current ROA % is 8.06% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Techne (MEX:TECH) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Techne stock appears to be undervalued.
The current stock price of MXN1,090.00 is trading 2.5% below its estimated GF Value™ of MXN1,117.60.
Key valuation signals for MEX:TECH:
ROA %: 8.06% (11% above median its 10-year median of 7.28)
GF Value™: MXN1,117.60 vs. price of MXN1,090.00 (2.5% below fair value)
No single metric tells the full story. See the MEX:TECH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
83GF Score
Get the complete analysis for MEX:TECH
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:TECH has been successfully added to your 
